A Phase 1 Single Center Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy

Beteiligte Wissenschaftlerin:
Dr. rer. medic. M. Eveslage

Studienleitung:
Univ.-Prof. Dr. med. Walter Stummer

The primary objective of the study is to evaluate safety and tolerability of SDT using 5-ALA + CV01-delivered SDT in newly diagnosed high-grade glioma. The secondary objectives are to assess radiological changes in response to 5-ALA + CV01-delivered SDT and to assess its histopathological efficacy. The study is an exploratory phase I, single-arm, single-center, investigator-initiated trial.